189 related articles for article (PubMed ID: 14593950)
1. [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
Wcisło G; Szczylik C
Pol Merkur Lekarski; 2003 Jul; 15(85):5-8. PubMed ID: 14593950
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
3. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
Kimyai-Asadi A; Usman A
J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant interferon treatment of melanoma].
Török L
Magy Onkol; 2003; 47(1):105-7. PubMed ID: 12704462
[TBL] [Abstract][Full Text] [Related]
5. Cytokine therapy in advanced melanoma.
Kalaaji AN
J Drugs Dermatol; 2007 Apr; 6(4):374-8. PubMed ID: 17668534
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant interferon-alpha in malignant melanoma: current status.
Hancock BW; Harris S; Wheatley K; Gore M
Cancer Treat Rev; 2000 Apr; 26(2):81-9. PubMed ID: 10772966
[TBL] [Abstract][Full Text] [Related]
9. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy.
Chao MM; Schwartz JL; Wechsler DS; Thornburg CD; Griffith KA; Williams JA
Pediatr Blood Cancer; 2005 May; 44(5):441-8. PubMed ID: 15468307
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant treatment of malignant melanoma: where are we?
Ascierto PA; Scala S; Ottaiano A; Simeone E; de Michele I; Palmieri G; Castello G
Crit Rev Oncol Hematol; 2006 Jan; 57(1):45-52. PubMed ID: 15990330
[TBL] [Abstract][Full Text] [Related]
11. [Interferon therapy in malignant melanoma].
Kokoschka EM; Micksche M
Wien Med Wochenschr; 1993; 143(16-17):441-2. PubMed ID: 8273369
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
Kirkwood JM; Tarhini AA
Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
[TBL] [Abstract][Full Text] [Related]
13. High-dose interferon versus GM2 vaccine in high-risk malignant melanoma.
Wilson K
J Clin Oncol; 2001 Dec; 19(23):4350. PubMed ID: 11731522
[No Abstract] [Full Text] [Related]
14. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
Lesinski GB; Valentino D; Hade EM; Jones S; Magro C; Chaudhury AR; Walker MJ; Carson WE
Cancer Immunol Immunother; 2005 Sep; 54(9):815-25. PubMed ID: 15668815
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
[TBL] [Abstract][Full Text] [Related]
17. Postsurgical adjuvant treatment of malignant melanoma patients by the thymic factor thymostimulin.
Azizi E; Brenner HJ; Shoham J
Arzneimittelforschung; 1984; 34(9):1043-7. PubMed ID: 6542371
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes and prognostic factors of high-risk malignant melanoma patients after surgery and adjuvant high-dose interferon treatment: a single-center experience.
Akman T; Oztop I; Unek IT; Koca D; Unal OU; Salman T; Yavuzsen T; Yilmaz AU; Somali I; Demir N; Ellidokuz H
Chemotherapy; 2014; 60(4):228-38. PubMed ID: 25870939
[TBL] [Abstract][Full Text] [Related]
20. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
